Ipca Laboratories Ltd. — Capital/Financing Update 2025

Oct 17, 2025

October 17, 2025

==> picture [105 x 47] intentionally omitted <==

THRU ONLINE FILING

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 023 Scrip Code – 524494

National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra – (East). Mumbai-400051. Scrip Code : IPCALAB

Dear Sir,

Sub: Outcome of Board Meeting held on 17[th] October, 2025

Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that the Board of Directors of the Company, at their meeting held on Friday, 17[th] October, 2025 have, inter-alia, approved the following :

As part of the Company’s operational strategy and to reduce number of manufacturing units and in order to minimize operational and other costs, the Company has decided to sell and transfer its drug intermediates and active pharmaceutical ingredients (APIs) manufacturing unit situated at GIDC Industrial Estate, Ankleshwar – 393 002, alongwith all rights, title and interest in the leasehold land, factory buildings, plant & machineries, employees, business, etc. with respect to the said manufacturing facility to M/s. Suleshvari Pharma Private Ltd. on a slump sale basis, subject to necessary approvals, for a consideration of Rs. 22.15 crores.

The sale of this manufacturing unit will not have any material impact on Company’s business and financials.

The summary of proposed transaction is tabulated below as per requirement of SEBI LODR Regulations :

1.	Manufacturingunit /facility proposed to be sold	Sale of the drug intermediates and bulk drugs manufacturing facility of the Company situated at leasehold Plot Nos. 4722, 4723, 4724, 4730, 4731 and 4732 at GIDC Industrial Estate, Ankleshwar – 393 002 (Gujarat) on a slump sale basis.

==> picture [445 x 70] intentionally omitted <==

==> picture [105 x 47] intentionally omitted <==

2.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	The revenue generated from this manufacturing unit in the financial year ended 31stMarch, 2025 was Rs. 50.24 crores (0.74% of the total income of the Company). The current written down value of the assets of this manufacturing unit in the Company’s books of accounts is Rs. 15.80 crores. The sale of this manufacturing unit will not have any material impact on the Company’s business and financials.
3.	Date on which the agreement for sale has been entered into	The agreement will be entered into in due course of time subject to necessary consent.
4.	The expected date of completion of sale	On or before 31stDecember, 2025 or such other date as may be mutually agreed subject to the necessary consent from GIDC for the transfer of the leasehold rights on the land on which this manufacturing unit is situated.
5.	Consideration receivable from such sale	Rs. 22.15 crores on a slump sale basis.
6.	Brief details of buyers and whether the buyer belong to the promoter/ promoter group/ group companies. If yes, details thereof;	M/s. Suleshvari Pharma Pvt. Ltd. It is a Company incorporated under the provisions of the Companies Act, 2013. It is engaged in the business of development, manufacture, distribution and sale of drug intermediates and bulk drugs. M/s. Suleshvari Pharma Pvt. Ltd. does not belong to the promoter/ promoter group of the Company and is not a related party.
7.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	This transaction does not fall within the purview of related party transactions.
8.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	The proposed sale of the undertaking is outside the scheme of arrangement.

==> picture [445 x 70] intentionally omitted <==

==> picture [105 x 47] intentionally omitted <==

9.	Name of the entity(ies) forming part of the slump sale, details in brief such as size, turnover etc.;	Please see information disclosed in Serial Nos. 1-6 above.
10.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	This transaction does not fall within the purview of related party transactions.
11.	Areaofbusinessofthe entity(ies)	The Company is engaged in development, manufacturing, marketing and distribution of pharmaceuticals. M/s. Suleshvari Pharma Pvt. Ltd. is also engaged in the business of development, manufacture, distribution and sale of drug intermediates & bulk drugs.
12.	Rationale for slump sale	Ongoing initiativeof optimization of manufacturing facilities of the Company and reducing number of smaller manufacturing facilities so as to reduce overall administrative and other operating costs.
13.	In case of cash consideration – amount or otherwise share exchange ratio	Cash consideration of Rs. 22.15 crores.
14.	Brief details of change in shareholding pattern (if any) of listed entity	There will not be any change in the shareholding pattern of the Company due to this sale of manufacturing facility.

Kindly note that the meeting started at 5.00 p.m. and concluded at 5. 2 0 p.m.

Thanking you

Yours faithfully

For Ipca Laboratories Limited

HARISH PANDURANG Digitally signed by HARISH PANDURANG KAMATH DN: c=IN, postalCode=400063, st=MAHARASHTRA, street=4204, TOWER B, OBEROI ESQUIRE ,YASHODHAM, MOHAN GOKHALE ROAD ,MUMBAI SUBURBAN,GOREGAON (EAST) ,400063, l=MUMBAI SUBURBAN, o=Personal, serialNumber=72050fb9fadcbc5de6404685117b8355792f5784c7617d9c4cae2a3887d6b809, pseudonym=cfedd4e63f0643129a1780871ed0cb04, 2.5.4.20=3e5648a57390d9262997da3de9051643bfb87e352b111402af42d20 KAMATH 7e52e25c6, email=HARISH.KAMATH@IPCA.COM, cn=HARISH PANDURANG KAMATH Date: 2025.10.17 17:22:27 +05'30'

Harish Kamath Corporate Counsel & Company Secretary

==> picture [445 x 70] intentionally omitted <==